Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001229466 | SCV001401911 | likely benign | Tuberous sclerosis 1 | 2024-11-12 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV004004831 | SCV004829811 | uncertain significance | Tuberous sclerosis syndrome | 2023-08-08 | criteria provided, single submitter | clinical testing | This missense variant replaces glutamine with lysine at codon 758 of the TSC1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with TSC1-related disorders in the literature. This variant has been identified in 1/251404 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004679017 | SCV005173412 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-06-14 | criteria provided, single submitter | clinical testing | The p.Q758K variant (also known as c.2272C>A), located in coding exon 16 of the TSC1 gene, results from a C to A substitution at nucleotide position 2272. The glutamine at codon 758 is replaced by lysine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |
Fulgent Genetics, |
RCV005050298 | SCV005674956 | uncertain significance | Lymphangiomyomatosis; Tuberous sclerosis 1; Isolated focal cortical dysplasia type II | 2024-06-05 | criteria provided, single submitter | clinical testing |